



AVICANNA™

A Biopharmaceutical Leader in Cannabinoid-Based Medicine

Q2 2026

TSX: AVCN

OTCQX: AVCNF FSE: ONN

avicanna.com

DISCLAIMER & NOTICE REGARDING FORWARD LOOKING STATEMENTS

Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations or other applicable securities laws (“forward-looking statements”). Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, milestones, expectations or intentions regarding the future including words or phrases such as “anticipate,” “objective,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is designed to” or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements and information about anticipated dates for revenue recognition; business strategy, product development, timing of product development, events and courses of action, anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical studies/trials and product development; expected results of clinical trials; the granting of any certifications, licenses, or registrations; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates, and beliefs. Forward-looking statements are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna may operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products.

Although we believe the assumptions underlying these forward-looking statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance, or achievements. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage operating expenses, which may adversely impact financial condition; ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; weather patterns; market conditions and the demand and pricing for products; demand and pricing of cannabis and cannabidiol; security threats, including loss/theft of proprietary technology; relationships with regulatory bodies, our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; ability to attract, retain and motivate qualified personnel; competition in our industry; ability to maintain technological leadership; impact of technology changes on our products and industry; failure to develop new and innovative products; ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; impact of intellectual property litigation that could materially and adversely affect our business; ability to manage working capital; dependence on key personnel; and additional risk factors included elsewhere in Avicanna’s public disclosures, including, without limitation, under the heading “Risk Factors” in its annual information form dated March 31, 2026 and final short form prospectus dated November 27, 2020, in each case filed with the Canadian securities regulators and available under Avicanna’s profile on SEDAR+ at www.sedarplus.ca.

Although Avicanna has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Avicanna is an early-stage company with a short operating history; and it may not actually achieve its plans, projections, or expectations. Important factors that could cause actual results to differ materially from Avicanna’s expectations include, consumer sentiment towards Avicanna’s products and cannabis and cannabis related technology generally, litigation, global economic climate, equipment failures, increase in operating costs, decrease in the price of cannabis and cannabidiol, security threats including a loss or theft of intellectual property, adverse medical findings, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, failure of counterparties to perform their contractual obligations, delays or unexpected expenditures in completion of clinical trials, or unexpected delays in the commercialization of products. Forward-looking statements contained in this presentation are as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Avicanna disclaims any intention or obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable securities law. Readers are cautioned that the forward-looking statements contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

All financial information included in this document is unaudited. There is a material risk that the audited financial results will differ significantly from the unaudited financial information presented herein. Certain information in this presentation is based on management estimates. Such estimates have been made in good faith and represent the current beliefs of management. Management believes that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are accurate, up-to-date, correct or complete. Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Avicanna believes that such information is accurate and that the sources from which it has been obtained are reliable. Where this presentation quotes any information or data from a third-party source, it should not be interpreted that Avicanna has adopted or endorsed such information or data as being accurate. Avicanna has not independently verified any of such information from third-party sources or any underlying assumptions. Accordingly, Avicanna makes no representation or warranty (express or implied) on the fairness, accuracy, completeness or correctness of any such third-party information.

No securities commission or similar authority of Canada, the United States or any other jurisdiction has reviewed or in any way passed upon this presentation, and any representation to the contrary is an offence. Readers should not construe the contents of this presentation as investment, legal, tax, regulatory, financial or accounting advice and are urged to consult with their own advisers in relation to such matters.



Integrated Cannabinoid-Based Biopharmaceutical Platform

A vertically integrated platform spanning API, R&D, clinical development, and patient care

Commercial & Medical Platform

- 4 integrated commercial-stage business units
- 50+ proprietary commercialized cannabinoid products
- Commercial presence across 20+ international markets
- \$25.5M revenue, near EBITDA breakeven during 2025

Scientific & Clinical Platform

- Proprietary intellectual property and formulation technologies
- Clinical and real-world evidence programs
- Partnerships with leading academic and clinical institutions
- Indication-specific pharmaceutical pipeline



Medical Cannabis Products (RHO Phyto™)



Medical Cannabis Care Platform (MyMedi.ca™)



Pharmaceutical Pipeline (Clinical Development)



Active Pharmaceutical Ingredients (Aureus™)

Rho Phyto™

Pharmaceutical-grade cannabinoid formulations



Standardized cannabinoid formulations across multiple delivery systems

Proprietary drug delivery systems designed to enhance bioavailability and dosing precision

Supported by pre-clinical, clinical, and real-world evidence

Multi-Cannabinoid Formulation Matrices 



A differentiated formulation platform bridging medical cannabis and pharmaceutical development

Innovation and Canadian Pipeline (2026)

Advanced And Evidence Based Nanotechnology Delivering Faster Onset Of Cannabinoids



Rapid Act Capsules



Rapid Act Soft Chews



Rapid Act Beverages



Oral Pouches



Controlled Release Tablets

Launching in Canada Q2 2026

QUIX RAPID ONSET
Nanotechnology

Q4 2026

PWDRX
TECHNOLOGY



Scaled Canadian Commercial & Medical Platform

Established National Distribution Across Medical Channels



170+

Commercial Placements
Across Canada

50+

Proprietary
Products

8

National Medical
Platforms (Including
MyMedi.ca™)

10

Manufacturing Partners
(Asset-Light Model)

Increasing contribution from proprietary, higher-margin products and medical channel distribution

MyMedi.ca™ | Nationwide Medical & Commercial Infrastructure

A proprietary platform enabling patient access, real-world evidence, and commercialization of cannabinoid-based therapies



Patient Onboarding & Support



Product Access & Fulfillment



Physician Engagement



Insurance & Reimbursement Coordination

Established through the acquisition of  **medical cannabis**
by **SHOPPERS** 

Enabling the transition from medical cannabis to pharmaceutical commercialization

MyMedi.ca™ | Nationwide Medical & Commercial Infrastructure

A proprietary platform enabling patient access, real-world evidence, and commercialization of cannabinoid-based therapies




Strategic Value

- Direct engagement with patients, prescribers, and payers
- Real-world evidence generation platform
- Enables reimbursement and formulary pathways

Commercial Impact

- Increasing proprietary product contribution
- Expanding medical channel penetration
- Platform for pharmaceutical commercialization
- Preferred vendor status with public and private insurance providers



A scalable platform driving patient access, data generation, and long-term pharmaceutical growth




Avicenna Academy | Medical Affairs & Clinical Education Platform

Supporting the integration of cannabinoid-based therapies into clinical practice



AVICENNA
ACADEMY



Core Capabilities

- Healthcare practitioner education and training
- Indication-specific clinical insights and case studies
- Scientific exchange and research collaborations with key opinion leaders
- Ongoing dissemination of emerging clinical evidence


Strategic Role

- Supports physician adoption and prescribing confidence
- Strengthens engagement with the medical community
- Reinforces evidence-based positioning

Enabling physician adoption and advancing
cannabinoid-based medicine into standard clinical practice

Pharmaceutical Pipeline | Indication-Specific Cannabinoid Therapeutics

Leveraging an integrated platform to develop proprietary, evidence-based drug candidates



Major Target Clinical Areas

Sleep

Epilepsy

Anxiety & Depression

Pain Management

Eczema/ Epidermolysis Bullosa

Positioned to advance from medical cannabis to pharmaceutical commercialization

*MyMedi.ca is operated by Northern Green Canada for the Canadian market

Pharmaceutical Pipeline | Status



Program	Indications	Formulation	Preclinical	RWE	Phase II/III	Registration
Trunerox™	Epilepsy (LG) and (DS)	Oral	○	○	○	●
AVCN319301a & AVCN319301b	Osteoarthritic Pain	Oral	●	●	●	○
AVCN583601	Epidermolysis Bullosa	Topical	●	●	○	○
AVCN467504	Local Inflammatory Pain	Topical	●	●	○	○

Legend ● = Completed / Active ○ = Planned

Trunerox 10% CBD

- First indication specific pharmaceutical product with marketing authorization
- Approved by INVIMA (Colombia) for Adjunctive Treatment of Seizures
- Associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS)
- 10% CBD proprietary formulation manufactured under GMP standards and utilizing the company's purified API



Osteoarthritis Pain | Phase II Clinical Program

A randomized, placebo-controlled clinical trial
evaluating oral cannabinoid-based therapies

Study Overview

- Phase II pilot clinical trial
- Oral cannabinoid formulations (CBD & THC capsules)
- Hip and knee osteoarthritis patients
- Funded by CIHR grant, sponsored by Avicanna

Clinical Design

- Randomized, placebo-controlled
- 3-arm parallel group study
- Evaluating pain interference outcomes
- Led by Dr. Hance Clarke

Large, underserved indication with significant
unmet need in chronic pain management



Aureus™ Active Pharmaceutical Ingredients Platform


Vertically integrated supply of cannabinoid APIs
supporting pharmaceutical and commercial operations

Infrastructure & Capabilities

- 300,000 sq. ft. cultivation and extraction facility (Colombia)
- Cultivation of CBD, THC, and CBG
- Organic and GACP-certified operations
- Commercial-scale production capacity

Strategic Role

- Reliable supply of pharmaceutical-grade cannabinoids
- Enables cost-efficient global manufacturing
- Integrated into Avicanna's commercial and clinical platforms
- Supplying APIs for approved pharmaceutical product (Trunerox™) and global commercial operations



Global Commercial Platform | International Expansion

Expanding cannabinoid-based pharmaceutical and medical products across




Commercial Presence and Potential

- 24 international markets served, across all continents
- Scalable platform supported by integrated API and manufacturing capabilities
- Platform for continued geographic expansion

Regulatory & Market Access

- Experience navigating international regulatory frameworks
- Product registrations and approvals across multiple jurisdictions and designations
- Expanding pathways for indication-specific pharmaceuticals



Positioned to scale internationally through a combination of regulatory expertise, supply chain control, and commercial partnerships

Established Scientific Platform & Institutional Validation

Supporting the development of
evidence-based cannabinoid therapeutics



Scientific Platform

- Proprietary formulation and delivery technologies
- Clinical and pre-clinical research programs
- Real-world evidence generation through MyMedi.caTM
- 100% ownership of all patents and IP

Scientific & Clinical Platform

- Partnerships with leading Canadian research institutions
- Multi-year academic and clinical collaborations
- Supported by non-dilutive government funding
- Collaborating with Canada's leading institutions since 2017

50+

Proprietary
Commercial Products



10+

Scientists



11

Government
Grants



20+

R&D
Collaborations



Financial Highlights | 2025 Performance

Strong margins, improving profitability, and disciplined capital structure



\$25.5M
Revenue



53%
Gross Profits



(\$0.29M)
Adjusted EBITDA
(near breakeven)



0 Debt
on the Balance Sheet

Profitability & Efficiency

- Significant improvement in EBITDA performance
- Expansion of gross margins to 53%
- Reduced operating expenses and improved cost structure


Capital Structure

- Debt-free balance sheet
- Limited dilution vs prior periods
- Supported by non-dilutive funding (grants, partnerships)



Positioned to achieve sustainable profitability while investing in clinical and commercial growth

2025 Revenue Breakdowns



Other Canadian Revenue



International Revenue



Pharmaceutical Pipeline



Growth Drivers

ST: Increase Avicanna's own SKUs proportion of MyMedi.ca sales

MT: Internationalization of MyMedi.ca

ST: Pipeline expansion with nanotechnology SKUs

MT: Licensing of proprietary formulations

ST: Aureus branded flower exports

MT: GMP certified Aureus branded products

MT: Export of proprietary finished products

ST: Commercialization and expansion of Trunerox

MT: Co-development, clinical development and licensing of pipeline candidatess

Management and Board of Directors



Senior Management Team

Aras Azadian
Founder and CEO

Nick Hilborn
Interim Chief Financial Officer

Stephen Kim
Chief Legal Officer & General Counsel

Ivana Marić
Executive Vice President, Marketing

Dr. Karolina Urban, PhD
Executive Vice President, Medical &
Scientific Affairs

Board of Directors

Aras Azadian
Founder and CEO

Lisa McCormack
Independent Director

Ozgur Kilic
Independent Director

Giancarlo Davila Char
Director

Michael Kott
Independent Director

Investment Highlights

Supporting the development of evidence-based cannabinoid

1. Integrated Platform

End-to-end capabilities spanning API, R&D, clinical research, and patient access

2. Pharmaceutical Pipeline

Indication-specific cannabinoid drug candidates across dermatology, pain, sleep, anxiety and neurology

3. High-Margin Commercial Business Units:

50+ proprietary products with growing contribution from medical platform

4. Global Expansion and Scale Opportunity

Commercial presence across 20+ international markets with scalable distribution model

5. Scientific & IP Leadership

Proprietary formulations, patents, and institutional collaborations supporting long-term differentiation



AVICANNA™



RHO™
PHYTO



MyMedi.ca
MEDICAL CANNABIS CARE



AUREUS
SANTA MARTA



Positioned to transition from medical cannabis to a global cannabinoid-based pharmaceutical company



AVICANNA™

Thank You

Q2 2026

TSX: AVCN

OTCQX: AVCNF

FSE: ONN

avicanna.com

info@avicanna.com

